Novel Salvage Regimens vs Conventional Chemotherapy Before ASCT in Patients With Relapsed/Refractory Classic Hodgkin Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
American Journal of Hematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma
Am. J. Hematol 2023 Jan 11;[EPub Ahead of Print], SH Desai, MA Spinner, K David, V Bachanova, G Goyal, B Kahl, K Dorritie, J Azzi, VP Kenkre, S Arai, C Chang, B Fusco, N Sumransub, H Hatic, R Saba, U Ibrahim, EI Harris, H Shah, J Murphy, S Ansell, D Jagadish, V Orellana-Noia, C Diefenbach, S Iyenger, KC Rappazzo, R Mishra, Y Choi, GS Nowakowski, RH Advani, IN MicallefFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.